Madison, Wis. (December, 2018) ‒ Recognized as the leader in nucleic acid delivery technologies, Mirus Bio announces the first instrument added to their product portfolio, the Ingenio® EZporator® Electroporation System. The new device is designed to be used with the Ingenio® Electroporation Solution, which is ideal for mammalian and insect cell transfection and has been part of Mirus Bio’s transfection solutions for a decade.

With this new system, researchers can expect:
• Performance: deliver any nucleic acid to hard-to-transfect, stem and primary cells
• Simplicity: use a single, universal electroporation solution across all cell types
• Flexibility: easily optimize electroporation parameters for each cell type

“It was a natural fit for Mirus to add the Ingenio® EZporator®,” said Josh Snow, Ph.D., Director of Business Development and Marketing Strategy. “Customers have been asking us for a complete system for hard-to-transfect cells. Our answer to this request is the EZporator®, an electroporator that is substantially more cost-effective than other products on the market and that complements our widely-used Ingenio® Electroporation Solution.”

“We believe the Ingenio® EZporator® Electroporation System will be the answer for many labs who are on a limited budget or just want to make their grant money go further,” added Snow. “Our customers also like the flexibility of the Ingenio® Electroporation Solution, which can be used on a wide array of electroporation devices and can be optimized for virtually any mammalian cell type.”

A purchase of a new EZporator® will also include a complimentary eight reaction (8 RXN) Ingenio® Electroporation Kit.
Please visit www.mirusbio.com/products/electroporation/ezporator for more information.

About Mirus Bio
TRANSFECTION: PROGRAMMING THE GENOME
Mirus Bio pioneered scientific breakthroughs in non-viral gene delivery and continues to produce industry-leading transfection reagents. As we continue to expand our expertise in nucleic acid delivery, we give life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing and genome editing.

CONTACT:
Josh Snow, Ph.D.
Director of Business Development and Marketing Strategy
Mirus Bio LLC
Ph: 608.229.1407
Fax: 608.441.2849
Email: josh.snow@mirusbio.com

Leave a Reply

Your email address will not be published. Required fields are marked *